期刊文献+

转运紫杉醇的PLGA纳米粒对膀胱癌的细胞毒作用 被引量:1

Formulation of paclitaxel loaded PLGA nanoparticle and it's cytotoxicity on bladder cancer
原文传递
导出
摘要 目的研究可转运紫杉醇的多聚体纳米粒对膀胱癌的细胞毒作用。方法应用微乳化方法制备载紫杉醇的聚乳酸-羟基乙酸共聚物(PLGA)纳米粒,以聚乙烯醇(PVA)为表面稳定剂,并以转铁蛋白(Tf)表面修饰,分析纳米粒的大小、表面电荷、载药浓度、药物释放曲线以及空白纳米粒的安全性,观察紫杉醇溶液及载紫杉醇纳米粒对膀胱癌细胞系J-82的细胞毒作用。结果PVA纳米粒直径约200nm,Z电势约-24mV,载药浓度约6.5%(w/w),药物释放曲线为双相性。Tf表面修饰的纳米粒直径比PVA纳米粒稍大,z电势、载药浓度、药物释放曲线与PVA纳米粒相似。两种空白纳米粒不具有细胞毒性。紫杉醇溶液在50ng/ml时J-82细胞存活率为82.0%,100ng/ml时为36.0%。PVA纳米粒在50ng/ml和100ng/ml时细胞存活率分别为40.2%和15.8%,而Tf纳米粒分别为32.9%和7.2%,两种载药纳米粒抑制J-82细胞的作用明显强于紫杉醇溶液。结论PLGA纳米粒是安全有效的载药工具,可以明显增强紫杉醇对膀胱癌的细胞毒作用。 Objective To formulate paelitaxel loaded polymer nanoparticle and evaluate it's application in treatment of bladder. Methods Paelitaxel loaded Poly (lactide-eo-glyeolide) (PLGA) nanopartieles were formulated with mieroemulsion method, Polyvinyl alcohol(PVA) was used as surfaetant. Trans- ferrin (Tf) was used to modify the nanoparticles. The size, Z-potential, drug loading, drug release, cytotox- icity of bland nanopartieles and paelitaxel-loaded nanoparticles on bladder cancer cell line J^82 were meas- ured. Results The size of nanopartieles was about 200 nm, Z-potential was -24 mV, drug loading was about 6.5% (w/w) , cumulative drug release showed two phase curve. The size of Tf modified nanoparticles was a little bigger than no modified nanoparticles. The Z-potential, drug loading, drug release was similar. Two kinds of blank nanoparticles showed no cytotoxieity on bladder cancer cell line J-82. However, both paclitaxel-loaded nanoparticles had significantly higher cytotoxicity on J-82 compared to paclitaxel solution. Conclusions PLGA nanopartiele is a promising drug delivery vehicle, which could significantly improve the antieanccr effect of paclitaxel on bladder cancer.
出处 《中华泌尿外科杂志》 CAS CSCD 北大核心 2013年第3期219-223,共5页 Chinese Journal of Urology
关键词 纳米粒 紫杉醇 膀胱肿瘤 Nanopartiele Paelitaxel Bladder neoplasms Carcinoma
  • 相关文献

参考文献12

  • 1Mei L, Zhang Y, Zheng Y, et al. A novel docetaxel-loaded poly (e-Caprolactone)/pluronic F68 nanoparticle overcoming multidrug resistance for breast cancer treatment. Nanoscale Res Lett, 2009, 4: 1530-1539.
  • 2Esmaeili F, Dinarvanda R, Ghahremani MH, et al. Cellular cytotoxicity and in-vivo biodistribution of docetaxel poly ( lactide- co-glycolide) nanoparticles. Anti-Cancer Drugs, 2010, 211 : 43- 52.
  • 3Sahoo SK, Panyam J, Prabha S, et al. Residual polyvinyl alco- hol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects tbeir physical properties and cellular uptake. J Control Re- lease, 2002, 82 : 105-114.
  • 4Vasir JK, Labhasetwar V. Biodegradable nanoparticles for cytosolic delivery of therapeutics. Adv Drug Deliv Rev, 2007, 59: 718- 728.
  • 5Sanna V, Roggio AM, Posadino AM, et al. Novel docetaxelloaded anoparticles based on poly (lactide-co-caprolactone) and poly (lactide-co-glycolide-co-caprolactone) for prostate cancer treatment: formulation, characterization, and cytotoxicity studies. Nanoscale Res Lett, 2011, 6: 260.
  • 6Nair KL, Jagadeeshan S, Nair SA, et al. Biological evaluation of 5-fluorouracil nanoparticles for cancer chemotherapy and its dependence on the carrier, PLGA. Int J Nanomed, 2011, 6: 1685-1697.
  • 7Lu Z, Yeh TK, Tsai M, et al. Paclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy. Clin Cancer Res, 2004, 10: 7677-7684.
  • 8Lu Z, Ych TK, Wang J, et al. Paclitaxel gelatin nanoparticles for intravesical bladder cancer therapy. J Urol, 2011, 185: 1478-1483.
  • 9Barthelmes J, Perera G, Hombach J, et al. Development of a mucoadhesive nanopartieulate drug delivery system for a targeted drug release in the bladder, lnt J Pharm, 2011, 416: 339-345.
  • 10Bilensoya E, Sarisozena C, Esendogli G, et al. Intravesical cat- ionic nanopartieles of chitosan and polycaprolactone for the delivery of Mitomycin C to bladder tumors. Int J Pharm, 2009, 371 : 170-176.

同被引文献3

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部